Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 24 Corporate Ct GUELPH ON N1G 5G5 |
Tel: | N/A |
Website: | https://www.zentek.com |
IR: | See website |
Key People | ||
Gregory Fenton Chief Executive Officer, Director | Wendy Ford Chief Financial Officer | Francis Dube Chief Operating Officer, Director |
Colin Van Der Kuur Vice President - Science and Research | Ryan Shacklock Vice President - Strategy, Business Development and Investor Relations |
Business Overview |
Zentek Ltd. is a Canada-based graphene technology company. The principal business of the Company is to develop opportunities in the graphene and related nano-materials industry based on its intellectual property, patents and unique Albany graphite. The Company is focused on the research, development, and commercialization of graphene-based products. The Company's technology helps filter and deactivate pathogens to reduce the risk of transmission. The Company is focused on commercializing ZenGUARD, which is a hydrophilic, water attracting coating that adsorbs bacteria and virus-laden aerosols and deactivates them, increasing public safety, and reducing the risk of transmission of COVID and other pathogens. The Company is developing a graphene-based fuel additive that can reduce greenhouse gas (GHG) emissions from diesel and bio-diesel fuels. The Company's developments include Aptamers & Rapid Detection and Graphene-Oxide Synthesis & Graphene Synthesis. |
Financial Overview |
For the nine months ended 31 December 2023, Zentek Ltd revenues decreased 62% to C$24K. Net loss decreased 21% to C$9.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Share-based compensation decrease of 48% to C$1.6M (expense), Consulting fees decrease of 53% to C$431K (expense), Government grants increase from C$21K to C$343K (income). |
Employees: | 27 as of Mar 31, 2023 |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $136.96M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.03M as of Dec 31, 2023 |
EBITDA (TTM): | -$12.33M as of Dec 31, 2023 |
Net annual income (TTM): | -$11.98M as of Dec 31, 2023 |
Free cash flow (TTM): | -$10.16M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 100,819,577 as of Feb 12, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |